Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 850.0
(0.7%)
INR 850.0
(0.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.75 Billion INR | 70.11% |
| 2022 | 3.88 Billion INR | -32.07% |
| 2021 | 5.71 Billion INR | -52.64% |
| 2020 | 12.07 Billion INR | 17.79% |
| 2019 | 10.24 Billion INR | 53.53% |
| 2018 | 6.67 Billion INR | 47.28% |
| 2017 | 4.53 Billion INR | -7.32% |
| 2016 | 4.89 Billion INR | -44.54% |
| 2015 | 8.81 Billion INR | 143.31% |
| 2014 | 3.62 Billion INR | 13.66% |
| 2013 | 3.18 Billion INR | 40.69% |
| 2012 | 2.26 Billion INR | 14.72% |
| 2011 | 1.97 Billion INR | 46.95% |
| 2010 | 1.34 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.67 Billion INR | -11.96% |
| 2023 Q2 | 1.4 Billion INR | 6.17% |
| 2023 FY | 6.6 Billion INR | 70.11% |
| 2023 Q1 | 1.32 Billion INR | -4.05% |
| 2023 Q3 | 1.96 Billion INR | 39.97% |
| 2023 Q4 | 1.9 Billion INR | -3.22% |
| 2022 Q2 | 1.65 Billion INR | 414.74% |
| 2022 FY | 3.88 Billion INR | -32.07% |
| 2022 Q3 | 1.82 Billion INR | 10.42% |
| 2022 Q4 | 1.38 Billion INR | -24.22% |
| 2022 Q1 | -524.4 Million INR | -241.65% |
| 2021 FY | 5.71 Billion INR | -52.64% |
| 2021 Q2 | 2.02 Billion INR | 10.86% |
| 2021 Q1 | 1.82 Billion INR | -37.08% |
| 2021 Q3 | 1.99 Billion INR | -1.44% |
| 2021 Q4 | 370.2 Million INR | -81.46% |
| 2020 FY | 12.07 Billion INR | 17.79% |
| 2020 Q4 | 2.9 Billion INR | -9.41% |
| 2020 Q3 | 3.2 Billion INR | -20.41% |
| 2020 Q2 | 4.02 Billion INR | 10.02% |
| 2020 Q1 | 3.66 Billion INR | 30.27% |
| 2019 Q1 | 1.92 Billion INR | 27.29% |
| 2019 FY | 10.24 Billion INR | 53.53% |
| 2019 Q4 | 2.81 Billion INR | -0.9% |
| 2019 Q2 | 3.09 Billion INR | 60.74% |
| 2019 Q3 | 2.83 Billion INR | -8.48% |
| 2018 Q4 | 1.51 Billion INR | -30.1% |
| 2018 Q1 | 1.23 Billion INR | -13.22% |
| 2018 Q2 | 2.76 Billion INR | 123.56% |
| 2018 Q3 | 2.16 Billion INR | -21.51% |
| 2018 FY | 6.67 Billion INR | 47.28% |
| 2017 Q2 | 1.61 Billion INR | 102.09% |
| 2017 FY | 4.53 Billion INR | -7.32% |
| 2017 Q4 | 1.42 Billion INR | -11.86% |
| 2017 Q3 | 1.61 Billion INR | 0.17% |
| 2017 Q1 | 797.5 Million INR | -29.88% |
| 2016 Q1 | 1.38 Billion INR | 13.69% |
| 2016 FY | 4.89 Billion INR | -44.54% |
| 2016 Q3 | 1.24 Billion INR | -21.01% |
| 2016 Q4 | 1.13 Billion INR | -8.74% |
| 2016 Q2 | 1.57 Billion INR | 14.18% |
| 2015 Q3 | 3.65 Billion INR | 0.71% |
| 2015 Q1 | 914.6 Million INR | 0.66% |
| 2015 Q4 | 1.21 Billion INR | -66.71% |
| 2015 FY | 8.81 Billion INR | 143.31% |
| 2015 Q2 | 3.62 Billion INR | 296.39% |
| 2014 Q4 | 908.59 Million INR | 2.27% |
| 2014 Q3 | 888.4 Million INR | -8.16% |
| 2014 Q2 | 967.3 Million INR | 0.06% |
| 2014 Q1 | 966.7 Million INR | 15.54% |
| 2014 FY | 3.62 Billion INR | 13.66% |
| 2013 Q2 | 927.1 Million INR | 29.7% |
| 2013 Q1 | 714.8 Million INR | 7.61% |
| 2013 Q3 | 1.02 Billion INR | 10.27% |
| 2013 FY | 3.18 Billion INR | 40.69% |
| 2013 Q4 | 836.71 Million INR | -18.15% |
| 2012 FY | 2.26 Billion INR | 14.72% |
| 2012 Q3 | 693.6 Million INR | 7.2% |
| 2012 Q4 | 664.26 Million INR | -4.23% |
| 2012 Q1 | 522.8 Million INR | 0.0% |
| 2012 Q2 | 647 Million INR | 23.76% |
| 2011 FY | 1.97 Billion INR | 46.95% |
| 2010 FY | 1.34 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aurobindo Pharma Limited | 42.2 Billion INR | 86.356% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 35.873% |
| Granules India Limited | 6.81 Billion INR | 15.53% |
| Indoco Remedies Limited | 1.29 Billion INR | -345.484% |
| Achyut Healthcare Limited | 4.43 Million INR | -129645.381% |
| Ajanta Pharma Limited | 19.67 Billion INR | 70.737% |
| Alkem Laboratories Limited | 19.46 Billion INR | 70.413% |
| Alpa Laboratories Limited | 184.49 Million INR | -3020.972% |
| Brooks Laboratories Limited | 14.44 Million INR | -39776.039% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -235.261% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -367.758% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 91.498% |
| Eris Lifesciences Limited | 5.18 Billion INR | -11.123% |
| FDC Limited | 2.98 Billion INR | -92.823% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 11.446% |
| Gufic Biosciences Limited | 1.32 Billion INR | -332.969% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -30.258% |
| Ipca Laboratories Limited | 7.98 Billion INR | 27.849% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -1033.194% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 3889.296% |
| Lasa Supergenerics Limited | -458 Million INR | 1357.213% |
| Laurus Labs Limited | 3.94 Billion INR | -45.826% |
| Lupin Limited | 28.04 Billion INR | 79.468% |
| Mankind Pharma Limited | 21.51 Billion INR | 73.241% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -5640.877% |
| Megasoft Limited | -121.1 Million INR | 4854.674% |
| NATCO Pharma Limited | 25.96 Billion INR | 77.821% |
| Piramal Pharma Limited | 4.55 Billion INR | -26.36% |
| RPG Life Sciences Limited | 2.29 Billion INR | -151.193% |
| Sigachi Industries Limited | 1.47 Billion INR | -290.672% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 94.479% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -24.968% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -2210.161% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -910.697% |
| Windlas Biotech Limited | 1.29 Billion INR | -343.309% |
| ZIM Laboratories Limited | 253.82 Million INR | -2168.496% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 86.642% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 239.928% |
| Divi's Laboratories Limited | 33.08 Billion INR | 82.593% |
| Hester Biosciences Limited | 364.81 Million INR | -1478.383% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -106.68% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -1158.48% |
| Bal Pharma Limited | 233.9 Million INR | -2361.684% |
| Strides Pharma Science Limited | 5.22 Billion INR | -10.186% |
| Venus Remedies Limited | 534.65 Million INR | -976.983% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -84.076% |
| Nectar Lifesciences Limited | 923.8 Million INR | -523.302% |
| Shilpa Medicare Limited | 1.36 Billion INR | -321.446% |
| Aarti Drugs Limited | 7.14 Billion INR | 19.453% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -260.602% |
| Suven Life Sciences Limited | -1.22 Billion INR | 569.734% |
| Ind-Swift Limited | 1.22 Billion INR | -369.679% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 59.685% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 249.448% |
| Themis Medicare Limited | 392.58 Million INR | -1366.699% |
| Hikal Limited | 32.11 Million INR | -17832.42% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 77.272% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -819.09% |
| Wockhardt Limited | -670 Million INR | 959.418% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -10.967% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -63394.216% |
| Neuland Laboratories Limited | 5.31 Billion INR | -8.274% |
| Morepen Laboratories Limited | 4.17 Billion INR | -37.957% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -2667.652% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -20870.573% |